Working closely with oncologists on value assessment frameworks can save money for the healthcare system while guaranteeing great outcomes for patients, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.
Working closely with oncologists on value assessment frameworks can save money for the healthcare system while guaranteeing great outcomes for patients, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.
Transcript (slightly modified)
Is Express Scripts using any of the value assessment frameworks to aid in formulary decision making?
We already are using value-based concepts. We actually work very close with ICER [Institute of Clinical and Economic Review], we've also been working very closely with Peter Bach, MD, and his DrugAbacus at Memorial Sloan Kettering. And so we look at, there are going to be opportunities to actually narrow formularies in oncology in the near future, which we've never had before. But it's going to take a level of sophistication and cooperation with the oncologists that we've never had before.
How are you working with oncologists to educate them about these new frameworks?
I'll be up at ASCO in just a couple of weeks. We actually view that we have got to have relationships. We've proved with hepatitis that if we have really close working relationships with the hepatologists we could get 96% cure rates and save $1 billion. We believe that same opportunity exists in oncology.
By working closer with the oncologists on care pathways, selection of drugs, introductions of biosimilars and generics for oncologic agents, we're going to be able to find areas where we can save money but also guarantee great outcomes for patients. And that really is the aim of the project.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen